Sculptra.com: For Healthcare Professionals

FOR U.S. RESIDENTS ONLY

	How Sculptra® Works
	Volumetric Improvement
	Safety and Tolerability
	Find a Sales Consultant
	Order Sculptra®
	Product Information

Enter your zip code to search for a healthcare provider near you.


Search by street address

Site (keyword)

Providers (zip code)

The History of Sculptra®

Sculptra® was approved by the FDA on August 3, 2004.

Sculptra® is injected into the skin for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus.

IMPORTANT SAFETY INFORMATION

Sculptra® is contraindicated in those individuals who have shown a hypersensitivity to any of its components. Sculptra® should not be injected in areas with active skin infection or inflammation. Avoid injection into the blood vessels.

The most commonly observed adverse event was the delayed occurrence of subcutaneous papules, which were confined to the injection site and were typically palpable, asymptomatic, and non-visible. Visible nodules, with or without inflammation or dyspigmentation, have also been reported. Other adverse events include immediate and transient injection-related events such as bleeding from the injection site, discomfort, erythema or inflammation, ecchymosis, and edema.

For more information, please see Full Product Information for Sculptra®